Research programme: p75 ligands - PharmatrophiX
Latest Information Update: 06 May 2016
At a glance
- Originator PharmatrophiX
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 09 Feb 2011 Elan discontinues development of P75 ligands
- 10 Aug 2009 Early research in Alzheimer's disease in USA (PO)